Compare YOU & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YOU | CRSP |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.8B |
| IPO Year | 2021 | 2016 |
| Metric | YOU | CRSP |
|---|---|---|
| Price | $41.07 | $57.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 22 |
| Target Price | $59.67 | ★ $87.56 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $900,779,000.00 | $289,590,000.00 |
| Revenue This Year | $23.34 | $1,063.30 |
| Revenue Next Year | $14.49 | $283.48 |
| P/E Ratio | $20.59 | ★ N/A |
| Revenue Growth | 16.91 | ★ 9169.85 |
| 52 Week Low | $29.44 | $44.12 |
| 52 Week High | $69.07 | $78.48 |
| Indicator | YOU | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 55.49 |
| Support Level | $37.38 | $50.56 |
| Resistance Level | $45.77 | $60.15 |
| Average True Range (ATR) | 1.57 | 2.92 |
| MACD | 0.49 | 0.04 |
| Stochastic Oscillator | 68.96 | 61.54 |
Clear Secure Inc is an identity company making experiences safer and easier digitally and physically. It is involved in creating a frictionless travel experience while enhancing security. Its secure identity platform uses biometrics to automate the identity verification process through lanes in airports, helping to make the travel experience safe and easy. The Company's operations are mainly focused on growing and maintaining its secure identity network across multiple offerings in both aviation and non-aviation channels.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.